Applications for new human medicines under evaluation: September 2025
Submitted by Anonymous (not verified) on 1 September 2025 - 12:46
Applications for new human medicines under evaluation: September 2025
Veterinary Dictionary for Drug Regulatory Activities (VeDDRA) dataload friendly file including deprecated terms
Submitted by Anonymous (not verified) on 1 September 2025 - 11:10
Veterinary Dictionary for Drug Regulatory Activities (VeDDRA) dataload friendly file including deprecated terms
Industry Standing Group meetings
Submitted by Anonymous (not verified) on 1 September 2025 - 11:09
Industry Standing Group meetings
14th Industry Standing Group (ISG) meeting, Online, European Medicines Agency, Amsterdam, the Netherlands, from 30 September 2025, 09:00 (CEST) to 30 September 2025, 13:15 (CEST)
Submitted by Anonymous (not verified) on 1 September 2025 - 11:08
14th Industry Standing Group (ISG) meeting, Online, European Medicines Agency, Amsterdam, the Netherlands, from 30 September 2025, 09:00 (CEST) to 30 September 2025, 13:15 (CEST)
The Connection Between Internal Medicine and Lifestyle Medicine
Submitted by Aneta on 1 September 2025 - 10:59
The EFIM Early Career Group is pleased to invite you to our upcoming webinar on “The Connection Between Internal Medicine and Lifestyle Medicine”, taking place on Wednesday, 24 September at 18:00 CEST.
This session will explore how lifestyle medicine can enrich internal medicine practice.
Join us for three inspiring presentations:
Administration and Corporate Management
Submitted by Anonymous (not verified) on 1 September 2025 - 10:40
Administration and Corporate Management
Organisation chart: Administration and Corporate Management
Submitted by Anonymous (not verified) on 1 September 2025 - 8:26
Organisation chart: Administration and Corporate Management
Human medicines European public assessment report (EPAR): Nintedanib Accord, nintedanib, Date of authorisation: 19/04/2024, Revision: 4, Status: Authorised
Submitted by Anonymous (not verified) on 29 August 2025 - 21:49
Human medicines European public assessment report (EPAR): Nintedanib Accord, nintedanib, Date of authorisation: 19/04/2024, Revision: 4, Status: Authorised
Human medicines European public assessment report (EPAR): Darzalex, daratumumab, Date of authorisation: 20/05/2016, Revision: 25, Status: Authorised
Submitted by Anonymous (not verified) on 29 August 2025 - 15:45
Human medicines European public assessment report (EPAR): Darzalex, daratumumab, Date of authorisation: 20/05/2016, Revision: 25, Status: Authorised
Human medicines European public assessment report (EPAR): Talzenna, talazoparib, Date of authorisation: 20/06/2019, Revision: 11, Status: Authorised
Submitted by Anonymous (not verified) on 29 August 2025 - 15:20
Human medicines European public assessment report (EPAR): Talzenna, talazoparib, Date of authorisation: 20/06/2019, Revision: 11, Status: Authorised